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Abstract
This paper designs an object-oriented, continuous-time, full simulation model for addressing a wide range of clinical, procedural,
administrative, and ﬁnancial decisions in health care at a high level of biological, clinical, and administrative detail. The full model
has two main parts, which with some simpliﬁcation can be designated ‘‘physiology models’’ and ‘‘models of care processes.’’ The
models of care processes, although highly detailed, are mathematically straightforward. However, the mathematics that describes
human biology, diseases, and the eﬀects of interventions are more diﬃcult. This paper describes the mathematical formulation and
methods for deriving equations, for a variety of diﬀerent sources of data. Although Archimedes was originally designed for health
care applications, the formulation, and equations are general and can be applied to many natural systems.  2002 Elsevier Science
(USA). All rights reserved.
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1. Introduction
Simulation models are distinguished from other types
of conceptual models by the fact that they include sim-
ulated objects, such as people, that correspond to real
objects, one-to-one. Simulation models vary greatly in
their breadth, depth, and realism. Our objective was to
design a very broad, deep, and realistic model that could
be used to address a wide range of clinical, administra-
tive, and ﬁnancial decisions in health care, at the level of
detail at which real decisions are made. Development of
such a model requires creating a population of simulated
individuals who have all the important events that occur
in real people and who respond to interventions in the
same way as real people. In health care, this requires
modeling all the essential aspects of human anatomy,
physiology, pathology, and response to medical treat-
ment. Because timing is an essential element of the oc-
currence, manifestation, progression, management, and
outcomes of diseases, the model must also be continuous.
This paper introduces the mathematical formulation
of such a model. The full model has two main parts,
which with some simpliﬁcation can be called the physi-
ology models and the models of care processes. The
models of care processes, while extremely detailed, are
straightforward from a mathematical point of view. In
contrast, the equations describing human physiology
and diseases are much more diﬃcult and are the subject
of this paper. Speciﬁcally, the paper describes how we
model human physiology and pathophysiology and how
the necessary equations can be derived from diﬀerent
types of data sources or research studies. Although this
model was originally developed for health care, its for-
mulation and equations are general and can be applied
to many natural systems.
2. Model formulation and deﬁnitions
The model is designed for object-oriented program-
ming. The major classes of objects in the model include
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people (members/patients), facilities, personnel, inter-
ventions, equipment, supplies, records, policies, and
budgets. This section describes how those models are
formulated, and the main deﬁnitions.
To avoid confusion, we will call the individuals in the
model ‘‘agents.’’ In the model, agents have physiologies
and organ systems (e.g., heart, kidney, blood system,
and immune system) just as real people do. (Agents also
have many other attributes—e.g., names, locations, be-
haviors, and education levels—which are not of concern
here.) In the model, as in reality, organ systems have
‘‘parts’’ and ‘‘functions.’’ Parts can have subparts and
subparts can themselves have subparts. For example, in
the model, the heart is composed of four coronary ar-
teries, heart muscle, valves, and other parts; each coro-
nary artery has multilayered walls and lumens
(channels); the lumens can be occluded by a thrombus at
any point.
All of these parts and subparts have functions that
correspond to those present in real people. For example,
the function of a coronary artery is to carry blood to the
heart muscle and the function of the heart is to pump
blood to other organs. As is true for real human organs,
a successful functioning of agents in the model depends
on all the agent’s parts and subparts functioning suc-
cessfully.
The physiology of an agent is characterized by
what we call ‘‘features,’’ which in health care corre-
spond to a wide variety of anatomic and biologic
variables. Examples of features in the model are blood
pressure, cholesterol levels (i.e., high-density lipopro-
tein [HDL] and low-density lipoprotein [LDL]), bone
mineral density, patency of a coronary artery, elec-
trical potentials of the heart (as recorded on an elec-
trocardiogram), contractility of myocardium, cardiac
output, visual acuity, and serum potassium level. A
feature can be continuously observable (e.g., a rash),
intermittently observable through tests (e.g., diameter
of a coronary artery), or not directly observable, ex-
cept through resultant events (e.g., ‘‘spread’’ of a
cancer).
At any time, every feature has a ‘‘value’’ (e.g., systolic
blood pressure of 140mmHg, 75% occlusion in the left
main coronary artery). Over time, the values of features
change. This progression causes every feature in every
individual to have a ‘‘trajectory,’’ which is deﬁned
mathematically as the value of the feature as a function
of time.
As in reality, the trajectory of a feature in a particular
agent can be aﬀected by the agent’s characteristics, be-
haviors, and other features. In health care, these are
often called ‘‘risk factors.’’ For example, the occlusion
of a coronary artery can be aﬀected by an individual’s
family history (genetics), sex, age, use of tobacco, blood
pressure, LDL cholesterol level, and many other risk
factors.
If no interventions are applied to change it, the tra-
jectory of a feature is called its ‘‘natural trajectory’’ or,
in the medical vernacular, its ‘‘natural history.’’
As in reality, when one or more features are consid-
ered ‘‘abnormal,’’ we say that an agent has a ‘‘disease.’’
Because in real life concepts of abnormality can change,
deﬁnitions of diseases can change. Furthermore, many
deﬁnitions of diseases are ‘‘manmade’’ and represent
gross simpliﬁcations of the underlying physiology, and
many diseases have diﬀerent deﬁnitions put forth by
diﬀerent experts. Therefore, what people call a disease is
actually a label we apply to a constellation of biological
variables according to particular rules. For example, a
person is said to have ‘‘diabetes’’ if their fasting plasma
glucose exceeds 125mg/dL or if their oral glucose tol-
erance test exceeds 199mg/dL. For these reasons, we
consider it important to model the underlying features
rather than whatever deﬁnition of a disease is current.
This approach is not only ﬂexible, but also addresses
comorbidities in a natural way through their underlying
biological variables. When we talk about a ‘‘disease
model,’’ such as the ‘‘diabetes model,’’ we are actually
referring to the set of biological variables and inter-
ventions that are pertinent to that disease.
At any time, the values or progression of many fea-
tures can be observed by ‘‘tests.’’ Examples are elec-
trocardiograms, blood chemistry panels, and X-ray
imaging. In this context, taking a patient’s history and
conducting a physical examination are also tests. In
health care, depending on whether a test is applied be-
fore the occurrence of any symptoms, after the occur-
rence of symptoms but before the diagnosis of the
disease, or after the diagnosis of the disease, the use of a
test is called ‘‘screening,’’ ‘‘diagnosis,’’ or ‘‘monitoring.’’
As a feature progresses, it can cause certain ‘‘events’’
to occur. In health care, these events are typically called
‘‘signs’’ (which are measured by tests), ‘‘symptoms’’
(which are directly experienced or felt by the patient,
such as a headache), or ‘‘health outcomes’’ (which are
the major symptoms and consequences of a disease such
as angina, heart attacks, and death). If an event is a
direct manifestation of a biologic feature (e.g., ‘‘mild
hypertension’’ or ‘‘hypercholesterolemia’’), the event is
called a ‘‘biologic event.’’ If an event is not a direct
manifestation of a feature but is caused by or associated
with a feature, as in angina caused by partial occlusion
of a coronary artery, we will call it a ‘‘clinical event.’’
For many diseases, there are ‘‘health interventions’’
that can change the value of one or more features, the
rate of progression of one or more features, or both the
value and rate of progression. Interventions can aﬀect
features either indirectly (by changing risk factors, e.g.,
smoking) or directly (by changing the feature itself).
Health interventions that have direct eﬀects can change
either the value of a feature (e.g., performing bypass
surgery to open an occluded coronary artery) or the rate
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of change of a feature (e.g., lowering cholesterol level to
slow the rate of occlusion). In addition to health inter-
ventions, there are ‘‘logistic interventions’’ that change
the way care is delivered. ‘‘Care processes’’ (e.g., in-
creasing the use of case managers, altering referral cri-
teria for specialists, or extending a clinic’s hours of
operation) can also change the way care is delivered. In
this paper, we will be concerned only with health in-
terventions and will use the term ‘‘intervention’’ in that
sense.
The occurrence of signs, symptoms, and outcomes
can set in motion a wide variety of ‘‘logistic events’’ in
the health care system. These in turn involve other
classes of objects in the model. For example, when chest
pain causes a person to call a hospital (a ‘‘behavior’’),
the person who answers the phone (a type of ‘‘person-
nel’’) determines the seriousness of pain (by applying a
particular triage ‘‘policy’’). The patient may go to an
emergency department (a type of ‘‘facility’’) where he or
she is seen ﬁrst by an ED nurse (another type of per-
sonnel), is asked to relate a brief medical history, and
receives a physical examination and then electrocardi-
ography (ECG) (all of which are ‘‘tests’’). Moreover,
electrocardiography uses an ECG machine (an item of
‘‘equipment’’) and ECG paper (a type of ‘‘supply’’).
The core of the simulation model is the set of
equations that describe the physiologies of individuals.
These include the equations that describe: (a) natural
trajectories of all the important features, including in-
teractions between features and the eﬀects of other risk
factors, (b) the occurrence of clinical events as a func-
tion of features, (c) the eﬀects of interventions on fea-
tures and on clinical events, and (d) the functions of
organs. This paper describes a general method for de-
riving equations for the ﬁrst two of these, based on ex-
isting data. The functions of organs and the eﬀects of
interventions are best described in terms of speciﬁc dis-
eases and are only summarized here.
3. Equations for trajectories of features
The equations for the features that deﬁne important
diseases depend on the number of features, the number
of events, and the available data. We will begin with the
simplest case in which a person has a single feature and
there are person-speciﬁc data on the values of the fea-
ture at a series of times. For example, think of the organ
being the heart, the part of the organ being a coronary
artery, the feature being the degree of occlusion of the
artery, and an event associated with the feature being a
heart attack. Later, we will discuss strategies when the
data are less good and extend the model to include ad-
ditional features, dependence of features on risk factors
(including other features), and the eﬀects of interven-
tions.
For each agent, we want to deﬁne a function that
describes the natural progression or trajectory of the
feature over time, from birth to death, where ‘‘natural’’
means the trajectory of the feature in the absence of any
special interventions from the health care system. Other
equations can then be used to simulate the eﬀects of
interventions.
Index a particular agent by k and let the trajectory of
the feature for the kth agent be F kðtÞ, where t is the time
since the agent’s birth (age). Because interventions can
change either the value of a feature or the rate of change
of a feature, we want to write a diﬀerential equation for
F kðtÞ. The general form of the diﬀerential equation for
each agent is
dF kðtÞ
dt
¼ RkðtÞ; ð1Þ
where F kðtÞ is the value of the feature at time t for the
kth agent and RkðtÞ is the rate at which the value of the
feature is changing at time t (the derivative). Either
F kðtÞ or RkðtÞ determines the natural trajectory for the
kth agent and either F kðtÞ or RkðtÞ can be determined
from the other. To simplify the description of the
methods, we focus here on the value of the feature,
F kðtÞ, with the understanding that the rate of change of
feature, RkðtÞ, can always be derived from F kðtÞ by
Eq. (1).
4. Trajectories of features as a random process
Our goal is to create a set of trajectories for a pop-
ulation of simulated agents that statistically match the
trajectories of a population of real people. We formulate
the problem as follows. Consider the trajectories of real
people to be a random (stochastic) process parameter-
ized by age (t). (As discussed later, the random process
can also be made conditional on risk factors, including
other features.) The sample space for the random pro-
cess for a particular feature is the collection of all pos-
sible trajectories, one for each person. Call this space X,
with elements x ¼ fx1;x2;x3; . . .g, where xk speciﬁes
the trajectory of the feature for a particular person. In
this space, the random process for the trajectories is
designated by upper-case boldface font, Fðx; tÞ. Each
function in Eq. (1) is a realization of the stochastic
process. That is, F kðtÞ ¼ Fðxk; tÞ ¼ xk all represent the
trajectory of the kth person in the set x.
The next step is to derive a distribution for the ran-
dom process from observations of real people. Once this
distribution has been derived, the third step will be to
draw trajectories from the distribution at random to
create new, simulated, agents. This process will guar-
antee that the trajectories of the simulated population
will statistically match the trajectories of the real
population.
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The process of estimating a distribution for the ran-
dom process involves two main steps: First, use person-
speciﬁc data to derive the samples that will deﬁne the
distribution and then determine the distribution from
the samples.
5. Deriving samples for estimating the distribution for the
random process
The general method for estimating a distribution for
the random process begins by writing the equation for
the trajectory of the feature as an expansion, each term
of which consists of a basis function weighted by a co-
eﬃcient. For each real person, we will ﬁnd the speciﬁc
values of the coeﬃcients that provide the best ﬁt to that
person’s data. Those values will become the samples
from which to derive the distributions for the coeﬃ-
cients, which in turn will determine the distribution for
the random process.
There are many ways to estimate the speciﬁc values
for the coeﬃcients, depending on how the basis func-
tions are chosen. Each method has strengths and
weaknesses. We will begin by describing a method based
on Fourier expansions that uses standard mathematical
techniques and is guaranteed to converge. To illustrate
the range of possible methods, we will also describe a
more intuitive method that is more closely related to the
familiar regression techniques used to analyze health
data. Unlike the Fourier expansion, the latter method,
which we will call the hybrid expansion, is not guaran-
teed to converge.
6. Determining samples by using the Fourier expansion
To derive the samples of the distribution for the ran-
dom process from person-speciﬁc data using a Fourier
expansion, expand the random process Fðx; tÞ (or any
function of Fðx; tÞ such as the log of the odds ratio of
Fðx; tÞ) in a Fourier-type series. Each term of the series
consists of two parts: an age-dependent, deterministic
(nonrandom) ‘‘basis’’ function (denoted as PjðtÞ for the
jth term in the expansion), multiplied by a coeﬃcient
that is a random variable (denoted by a lower-case
boldface letter) and is independent of age, f jðxÞ. Thus,
Fðx; tÞ ¼
X1
j¼0
f jðxÞPjðtÞ: ð2Þ
The basis functions PjðtÞ could be any complete set of
functions. Some examples are: a polynomial series, i.e.,
tj; the jth Legendre or Laguerre polynomial; or a clas-
sical Fourier series, i.e., sinðjt=T Þ. When the basis
functions are chosen to be orthonormal over the range
of ages of interest, then the expansion is called a
Karhunen–Loeve (K–L) decomposition [1–5]. Because
the theory of K–L decompositions is reasonably well
developed and because the K–L decomposition has
several advantages, there are good reasons to choose the
PjðtÞ to be orthonormal. The Legendre, Laguerre, and
Fourier functions are all orthonormal.
Whatever basis functions are chosen, they will be the
same for every person or agent. However, because the
coeﬃcients f jðxÞ are random variables, they are diﬀer-
ent for each person or agent. The choice of basis func-
tions thus aﬀects the coeﬃcients calculated and the rate
of convergence for the series (i.e., number of terms
needed to ﬁt the data) but will not prevent the method
from working.
The task now is to estimate the samples that will be
used to derive the distributions for the coeﬃcients f jðxÞ.
In practice, the sum in Eq. (2) is truncated to a ﬁnite
number of terms, J þ 1, which is related to (but not
greater than) the number of events observed for each
person. The method for estimating the samples for the
f jðxÞ depends on the available data. In the best case,
there are person-speciﬁc data that provide a series of
values of the feature at speciﬁed times for a large
number of people. For example, there might be a series
of measurements of intraocular pressures for a group of
people. There is no requirement that the measurements
for each person be taken at the same times.
The function describing the trajectory for the kth real
person is approximated by a ﬁnite sum,
F kðtÞ 
XJ
j¼0
f kj PjðtÞ; ð3Þ
where f kj are the coeﬃcients determined to ﬁt the data
observed for the kth person. The f kj are the samples that
will be used to estimate the distribution of the coeﬃ-
cients f jðxÞ. Although many diﬀerent ways can be used
to estimate the f kj from the data, we outline three
methods here: (a) the ﬁrst requires the expansion in Eq.
(3) to pass through all of the observed points, (b) the
second uses the method of least squares, and (c) the
third uses the orthonormal properties of PjðtÞ.
For the ﬁrst method, imagine that for each person
there are J þ 1 observations. This will lead to J þ 1
equations with J þ 1 unknowns, the f kj . This linear
system of equations can be solved for the f kj using
standard methods.
The second method, least squares, is useful when the
number of terms is less than the number of observations
for each person. For example, if there are M observa-
tions that can be used to determine coeﬃcients for the
J þ 1 terms, where J < M , then the f kj can be deter-
mined by minimizing the sum of the squares of the
diﬀerences between the value of the function and the
value of the expansion on the right-hand side of Eq. (3)
at all of the M points. The expression to be minimized
for this method, for the kth person, is
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Xm¼M
m¼1
F kðtmÞ
 
	
Xj¼J
j¼0
f kj PjðtmÞ
!2
: ð4Þ
Taking the derivative of this equation with respect to
each f kj (j ¼ 0 to J ) and setting this derivative to zero
produces a set of linear equations that determine the f kj .
The third way to determine the f kj makes use of the
orthonormal properties of the PjðtÞ. Multiplying both
sides of Eq. (3) by PiðtÞ 
 W ðtÞ (where W ðtÞ is the
weight for the chosen set of orthonormal functions) and
using the orthogonality property directly yield the fol-
lowing expression for f kj :
f kj ¼
Z
F kðtÞ 
 PjðtÞ 
 W ðtÞdt: ð5Þ
The observed points are used to approximate the inte-
gral. As before, there must be at least J þ 1 observa-
tions. The coeﬃcients determined in this way will
minimize the integral of the square of the diﬀerence
between the right and left sides of Eq. (3). That is, the
coeﬃcients calculated by Eq. (5) will minimizeZ
F kðtÞ
 
	
Xj¼J
j¼0
f kj PjðtÞ
!2
W ðtÞdt: ð6Þ
The theory of this type of expansion is called functional
analysis. An important advantage of this method is that
the power of the theory of functional analysis can be
applied to the estimation procedure. Moreover, many
properties of the K–L decomposition require the use of
this type of expansion.
For any set of basis functions chosen initially, any of
these three methods can be used to ﬁnd values of the
coeﬃcients that cause each person’s trajectory to ﬁt the
data. At this point, we can create ‘‘clones’’ of the orig-
inal population, i.e., agents whose trajectories match,
person for person, the trajectories of real persons. These
agents could be used to explore outcomes and eﬀects of
interventions in the original population.
As valuable as that might be, however, creating only
clones would not enable us to simulate other popula-
tions diﬀerent in size, risk factors, and other character-
istics. To do that, we need to create agents that
statistically match, but are not identical to, the real
people. This is accomplished in three steps: (1) for each
coeﬃcient, calculate the values of f kj for a large number
of real people; (2) use these values to estimate distribu-
tions for each f jðxÞ; (3) draw new values from the dis-
tributions to create new simulated individuals (agents).
7. Ensuring ﬁrst-order independence of fjðxÞ
Before proceeding to calculate distributions for the
f jðxÞ, however, it is important to determine if they are
independent, at least to the ﬁrst order. If they are, a
particular agent could be created by drawing values for
each of the j random variables f jðxÞ and then using Eq.
(3) to calculate a particular simulated trajectory. But it is
very unlikely that the f jðxÞ are independent. The pres-
ence and degree of covariance or correlation between the
fjðxÞ can be determined and appropriate corrections
can be made, as follows.
If the f jðxÞ are independent, then their covariance
should be zero. To determine if this were true, we ﬁrst
transform the values of f kj for each person by sub-
tracting out the mean of the values of the coeﬃcient.
(We represent the mean of a coeﬃcient with angle
brackets.) Thus, for the jth coeﬃcient
fj
  ¼ 1
K
XK
k¼1
f kj ; ð7Þ
where K is the total number of individuals for which
data exist. Then for the kth individual, subtracting out
the means of each coeﬃcient in Eq. (3) yields
F kðtÞ ¼
XJ
j¼0
ðf kj
 
	 fj
 ÞPjðtÞ
!
þ
XJ
j¼0
fj
 
PjðtÞ
 !
: ð8Þ
The coeﬃcient of the ﬁrst term on the right is the
original coeﬃcient with the mean subtracted out. The
last term on the right is required to maintain the equality
of the two sides, and can be thought of as the average
trajectory—the basis functions weighted by the average
values of the coeﬃcients. We will represent the average
trajectory as FðtÞh i. That is,
FðtÞh i ¼
XJ
j¼0
fj
 
PjðtÞ: ð9Þ
Let q represent the transformed values for the coeﬃ-
cient; that is, for the jth coeﬃcient and the kth person
qkj ¼ f kj 	 fj
 
: ð10Þ
This gives a new equation for the trajectory of the fea-
ture. Substituting Eqs. (9) and (10) in Eq. (8) yields
F kðtÞ ¼
XJ
j¼0
qkjPjðtÞ þ FðtÞh i: ð11Þ
Now deﬁne the covariance matrix C with elements Cij,
where
Cij ¼ 1K
XK
k¼1
qki q
k
j : ð12Þ
If the random variables for the original coeﬃcients
f jðxÞ are independent, then the oﬀ-diagonal terms of
the covariance matrix will be 0. In such cases, it is ap-
propriate to create new simulated agents by drawing
values from the distributions of the random variables
for the coeﬃcients and using these values in Eq. (3) to
derive simulated trajectories for as many agents as
desired.
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When the original coeﬃcients are not independent,
which is the usual case, two main approaches are
possible: (a) estimate a joint distribution for the f jðxÞ
and create simulated agents by drawing from that
joint distribution; or (b) use the covariance matrix to
determine a new set of basis functions, QjðtÞ, and new
coeﬃcients, sjðxÞ, that are not correlated. (The co-
variance is zero.) The latter approach requires fewer
data, is computationally simpler, creates an optimal
expansion, and can provide powerful insights into the
behavior of the feature. This approach is closely re-
lated to both the principal component method (PCM)
and the method of factor analysis and is a central
feature of the K–L decomposition. After the new,
uncorrelated coeﬃcients sjðxÞ have been determined,
if there are any higher-order correlations, then it is
much easier to estimate their joint distribution and
draw from that distribution to create simulated agents.
(Under some conditions, the new coeﬃcients will also
be independent.)
The second approach is accomplished as follows.
Because the covariance matrix is real, symmetric, and
nonnegative, it has J þ 1 real eigenvalues kj (with
kj P 0) and J þ 1 orthonormal eigenvectors wj. The ei-
genvectors and eigenvalues have two important prop-
erties. First, multiplying an eigenvector by the matrix
from which it was derived reproduces the eigenvector
scaled by the eigenvalue. Thus,XJ
l¼0
Cjlw
n
l ¼ knwnj ðj ¼ 0 . . . J ; n ¼ 0 . . . JÞ: ð13Þ
Second, the eigenvectors are orthonormal,
XJ
j¼0
wnjw
l
j ¼ dnl; ð14Þ
where dnl ¼ 0 if n 6¼ l, and dnl ¼ 1 if n ¼ l. Moreover,
the eigenvectors span the space so that any vector can be
represented as the sum of coeﬃcients times the eigen-
vectors.
Using the eigenvectors of the covariance matrix, it is
possible to calculate new coeﬃcients and basis vectors
for the expansion of the trajectory that have the desired
property that the coeﬃcients are uncorrelated. The ﬁrst
step in this calculation is to expand the coeﬃcients qkj
calculated for each person from Eq. (10) in terms of the
eigenvectors and new coeﬃcients ski ,
qkj ¼
XJ
i¼0
ski w
i
j: ð15Þ
Eq. (15) can then be used to solve for the ski in terms of
the qkj . Multiplying each side by the nth eigenvector and
summing over its elements yield
XJ
j¼0
qkjw
n
j ¼
XJ
j¼0
XJ
i¼0
ski w
i
jw
n
j : ð16Þ
But by Eq. (14) and the orthogonality of the eigen-
vectors,
XJ
j¼0
XJ
i¼0
ski w
i
jw
n
j ¼ skn: ð17Þ
This equation deﬁnes the new coeﬃcients in terms of the
qkj and the eigenvectors; the new coeﬃcients are a linear
combination of the old coeﬃcients and are weighted by
the elements of the corresponding eigenvectors. Thus,
for the nth new coeﬃcient, we obtain
skn ¼
XJ
j¼0
qkjw
n
j : ð18Þ
Similarly, we can deﬁne new basis vectors QjðtÞ as linear
combinations of the old basis vectors weighted by the
elements of the eigenvectors. That is,
QnðtÞ ¼
XJ
j¼0
wnj PjðtÞ: ð19Þ
Using Eq. (18) we can verify that the coeﬃcients sjðxÞ
and snðxÞ are not correlated. Thus,
sjðxÞsnðxÞ
 ¼ð1=KÞXK
k¼1
XJ
i¼0
qki w
j
i
 ! XJ
l¼0
qklw
n
l
 !
; ð20Þ
¼
XJ
i¼0
XJ
l¼0
Cilw
j
iw
n
l ¼
XJ
i¼0
knw
j
iw
n
i ¼kndjn:
ð21Þ
Further, by substituting the new coeﬃcients and basis
functions, we can verify that these new coeﬃcients and
basis functions satisfy the original equation for the tra-
jectory of the feature. Substituting Eq. (15) in Eq. (11)
thus yields
F kðtÞ ¼ FðtÞh i þ
XJ
j¼0
XJ
l¼0
sklw
l
jPjðtÞ ð22Þ
and substituting Eq. (19) in Eq. (22) yields
F kðtÞ ¼ FðtÞh i þ
XJ
l¼0
sklQlðtÞ: ð23Þ
To summarize, starting from an arbitrary set of basis
functions, PjðtÞ, this method can be used to derive a set
of basis functions, QjðtÞ, that cause the trajectories of
real persons to best ﬁt the observed data (e.g., passing
through all observed points), but for which the coeﬃ-
cients, sjðxÞ, are uncorrelated.
This method of expansion has many advantages.
First, it corrects for ﬁrst-order correlations. If the ran-
dom process is Gaussian, then correcting for ﬁrst-order
correlations corrects for all higher-order correlations
and, consequently, makes the random variables sjðxÞ
independent. (Loosely speaking, the random process
Fðx; tÞ is Gaussian if for an arbitrary set of times t0 the
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Fðx; t0Þ are jointly Gaussian.) Although assuming a
Gaussian distribution is frequently reasonable, the
method does not correct for higher-order correlations. If
higher-order correlations are found to be important,
then forming the joint distribution of the sjðxÞ may still
be necessary. Even in this case, however, forming these
joint distributions from Eq. (23) will still be easier be-
cause the ﬁrst-order correlations would have been re-
moved.
A second advantage of this method is that it provides
insight into the nature of the trajectory of the feature.
The K–L expansion can be shown to be optimal in the
sense that if the expansion in Eq. (2) is truncated at the
mth term, the mean square error is smallest if the basis
functions are the QjðtÞ and the coeﬃcients of the ex-
pansion are the skj as derived above. By exploring the
rate at which the expansion converges when diﬀerent
basis functions are used and by exploring the behavior
of the components of the expansion’s trajectory (the
QjðtÞ) we can learn about the biology of the feature.
Also, using the new basis functions is likely to make the
expansion converge faster in the sense that fewer terms
are needed to get a good ﬁt of the data. This can provide
information about the minimum number of observa-
tions needed to formulate an accurate description of the
feature’s trajectory: the number of data points needed is
equivalent to the number of expansion terms that have
important coeﬃcients. For example, if the data are well
ﬁtted by using only two terms in the expansion, only two
data points will be needed to ﬁt the entire function. This
fact can have important consequences for future data
collection.
We can assess the importance of each term in the
expansion by examining the sizes of the eigenvalues kn.
This process is similar to factor analysis. The covariance
matrix has diagonal elements r2n, where r
2
n ¼ 1=KPK
k¼1ðqknÞ2. The sum of the diagonal elements of C is
r2 ¼PJn¼1 r2n. This sum is conserved in diagonalization,
so the sum of the eigenvalues is also r2. Just as in factor
analysis, the size of each eigenvalue represents the im-
portance of each term in the expansion of the process;
the terms with the largest eigenvalues contribute the
most to the convergence of the series. Consequently, the
number of terms in the expansion can be reduced by
keeping only those that have the largest eigenvalues.
One frequently used method is to order the eigenvalues
by size, calculate their sum, and retain the ﬁrst m ei-
genvalues such that
Pi¼m
i¼0 ki PFrac 
 r2, where Frac is
the percentage of the original variance the reduced ei-
genvector set will reproduce. Frac is typically chosen to
be about 0.9. Standard (but nonetheless empirical)
methods of choosing the number of eigenvalues to retain
in the factor analysis method are described elsewhere
[6,7].
In summary, the Fourier expansion with the K–L
decomposition produces a new set of coeﬃcients that are
easier to use because they are uncorrelated (and perhaps
independent). If higher-order correlations exist, then the
K–L procedure makes ﬁnding the joint distribution of
the coeﬃcients easier. In addition, because the expan-
sion is optimal, fewer terms in the series may be needed
to adequately represent the random process. The K–L
procedure also enables identiﬁcation of terms to be re-
tained. A drawback of the Fourier expansion is that the
terms of the expansion equations, either before or after
transformation, are abstract and do not correspond to
real biological variables. They will calculate the trajec-
tory of a feature accurately, but will have little if any
intuitive or biological interpretation.
8. Determining samples using the hybrid expansion
In some cases, the use of some nonstandard functions
may be helpful as part of the set of basis functions. For
instance, when it is reasonable to believe that a feature
depends strongly on one or more other features, it
would be natural to try to incorporate that dependence
explicitly into the basis functions. For example, occlu-
sion of a coronary artery (F1) is known to depend on
both blood pressure (F2) and cholesterol level (F3),
among other features. These features can be included in
the expansion for F1 as follows:
(a) As before, denote the set of basis functions as PjðtÞ.
However, instead of choosing the PjðtÞ to be ortho-
normal, let P0ðtÞ represent the blood pressure level
and let P1ðtÞ represent the total cholesterol level
for that person. Additional basis functions could
be chosen to address dependencies or other relations
between features. For example, we could let P2ðtÞ
represent the product of blood pressure and total
cholesterol levels and let P3ðtÞ represent the product
of three values: t, blood pressure level, and choles-
terol level. As in the Fourier expansion, the remain-
ing basis functions would be the orthonormal set.
(b) After the ﬁrst few basis functions are chosen to in-
clude other features, the remainder of the analysis
can proceed as for the Fourier expansion, except
that Eq. (5) cannot be used to determine the coeﬃ-
cients (i.e., because the full set of basis functions is
no longer orthonormal). However, the other equa-
tions will still apply. For example, the covariance
matrix can still be diagonalized to obtain a new set
of basis functions having the desired properties. No-
tice, however, that the ﬁrst few basis functions will
be diﬀerent for every person because the functions
describe the progression of a particular feature for
a particular person.
This type of hybrid expansion is related to the ex-
pansions traditionally used in regression analyses. The
independent variables in a regression equation corre-
spond to the basis functions in our model and the
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coeﬃcients correspond to our coeﬃcients. However,
there are important diﬀerences: the basis functions in
our model are usually functions of time and our coef-
ﬁcients are random variables. Nonetheless, both models
explicitly include other features as terms in the expan-
sion.
The hybrid expansion has several advantages: (a) it
is intuitively appealing; (b) unlike the Fourier expan-
sion, its basis functions correspond to biological vari-
ables and have immediate clinical interpretations; (c) it
corresponds to regression models, which are familiar;
and (d) it can determine how important is the depen-
dence of one feature on another (e.g., the importance
of blood pressure level in determining the progression
of coronary artery occlusion). Moreover, the hybrid
expansion can converge even faster than can the Fou-
rier expansion.
However, the hybrid expansion also has several dis-
advantages: (a) whereas the Fourier expansion is guar-
anteed to converge under very general conditions, the
hybrid expansion is not; (b) the hybrid expansion is not
as mathematically rigorous as the standard method; and
(c) some matrices of the hybrid expansion may be ill
conditioned and diﬃcult to invert. Nonetheless, the
hybrid expansion may be a useful practical approach,
especially when data or existing regression models de-
scribe the dependence of one feature on other features.
Because data were available from the Framingham
study [8], we chose the hybrid expansion for modeling
coronary artery occlusion.
9. Using samples to determine the distribution for the
random process
Determining the distribution of a random variable
from a set of samples (skij) is a standard problem that is
often addressed using maximum likelihood techniques.
We ﬁrst review the application of this technique for a
feature that does not depend on any other features. We
then show how to include dependence on other features.
Designate the samples as skij, where k represents the
kth individual, j represents the jth term in the expansion,
and i represents the ith feature. We denote the proba-
bility distribution of the random variable for the sam-
ples, sijðxÞ, as qij. qij is characterized by a small number
of parameters:
qij xjhij1 ; hij2 ; . . . hijN
 	
dx ¼ qij xj~Hij

 
dx
¼ P ðx < sijðxÞ < xþ dxÞ: ð24Þ
In this equation, Pð::Þ is the probability that the random
variable sijðxÞ lies in the range between x and xþ dx,
conditional on the ~Hij, where ~H
ij ¼ fhijn ; n ¼ 1 . . .Ng are
the parameters of the distributions of the coeﬃcients
sijðxÞ. The probability of obtaining the samples skij is the
likelihood and is related to the distribution qij and to the
samples skij by the likelihood function
L ~Hijjs1ij; s2ij; . . . sKij

 
¼
YK
k¼1
qij s
k
ijj~Hij

 
: ð25Þ
An estimate of the parameters ~Hij is obtained by max-
imizing the likelihood as a function of the parameters
~Hij.
10. Incomplete data
The methods just described can be applied when there
are person-speciﬁc data for the values of the feature for
several times (but not necessarily at the same times for
each person.) This is realistic for many problems today
and is a restriction shared by most statistical models,
such as regression models. Moreover, person-speciﬁc
data are likely to become far more available with
increased use of automated clinical information systems.
Today, however, there are many clinical conditions
for which a biological feature is diﬃcult or impossible to
observe and for which the only data available relate to
occurrences of clinical events. For example, several large
epidemiologic studies provide data on the probability of
a heart attack for people of various ages, but no large
studies provide data on the degree of occlusion of cor-
onary arteries (because the required measurement en-
tails use of a risky, expensive test). In such cases, the
choice of an approach depends on the availability of
data from ancillary sources on the relationship between
the feature and a clinical event. For example, Roberts [9]
has reported the degree of occlusion in patients who
recently had a heart attack. When available, data like
these can be used to translate epidemiologic data on
clinical events into estimates of values of the feature,
and the process described can be used to complete the
derivations of equations for the trajectory of the feature.
When there are no data at all on the value of the
feature at the time of clinical events, a diﬀerent ap-
proach can be used. In this case, the objective is no
longer to write equations for the trajectory of the true
values of the feature, because that is not possible if there
are truly no systematic observations of the feature. In-
stead, the objective can be thought of as to write equa-
tions for an imaginary or virtual feature whose only
purpose is to accurately reproduce the observed occur-
rences of clinical events. For this purpose, the feature
can be assigned an arbitrary value when the event oc-
curs. If there are more than one clinical events to be
simulated, the arbitrary values should obviously corre-
spond to the order in which the events occur. If the
events occur in diﬀerent orders in diﬀerent people,
chances are good that the events are caused by diﬀerent
features, and equations for each feature can be derived
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accordingly. Although this approach is worthless for
providing information about the true value of the virtual
feature, it does provide what is needed for an accurate
simulation of clinical events at rates that match the oc-
currences of real clinical events.
The last case arises when there are no person-speciﬁc
data and the only available data are aggregated over a
population. For example, there may be data on the age
distribution of patients diagnosed with various stages of
a cancer, but no person-speciﬁc data on the ages at
which particular individuals pass through each stage. Of
course, if there are data from other sources that relate
the clinical events to the values of the feature (in this
example the stage of the cancer), those data should be
used to resolve the problem as described in the previous
section. Assuming that there are no such data, there are
two main options, depending on whether there is reason
to believe that the clinical events are correlated. If it is
reasonable to assume that they are not correlated, then
they can be modeled as if caused by two diﬀerent fea-
tures, and the modeling problem is reduced to a case we
have already discussed. If it is not reasonable to assume
that the events are uncorrelated, then we have to pos-
tulate a model that describes the correlation. We would
ﬁrst look for any data on which our presumption of
correlation was based and use those data to develop a
model. But even if no such data are available, there may
be plausible reasons to postulate a model. For example,
we might assume that some individuals have an ‘‘ag-
gressive’’ form of cancer, implying that they will move
through each stage relatively rapidly, whereas others
may have a more ‘‘indolent’’ form, implying that their
cancer will tend to progress more slowly. Thus, if a
person with aggressive disease was in the ﬁrst 10% in
terms of the age at which the ﬁrst stage of the disease
developed, we might be willing to assume that he will be
in the ﬁrst 10% in the pace at which he progresses
through subsequent stages. Once a speciﬁc correlation
is postulated, then it is possible to convert the cross-
sectional data into a set of person-speciﬁc longitudinal
data and the problem is transformed into the original
case.
It is important to emphasize that whether or not as-
sumptions of the type described in this section must be
made, the ultimate test of the quality of the model will
be whether it can reproduce whatever data exist. If it
can, the model should be useful. If it cannot, the model
should not be used for a problem involving that feature
until better data are available. These issues are ad-
dressed in the validation of the model.
11. Multiple features and interdependence of features
The equations for multiple features depend on the
extent to which features are independent in the sense
that they depend only on time (e.g., a person’s age) and
do not depend on other features or other factors that
may vary across individual persons. It should be ap-
parent that for features that are independent in this
sense and depend only on an individual’s age, the
methods already described can be used to derive equa-
tions for as many such features as desired. The diﬃ-
culties arise when the trajectory of a feature depends on
other features or other risk factors.
This is a common occurrence. For the example of
coronary artery disease, the rate of coronary artery
occlusion depends not only on age but also on other
features, such as cholesterol level, blood pressure level,
tobacco use, and diabetes. Collectively, we call these
‘‘risk factors,’’ with the understanding that this term
covers a wide range of disparate factors. Some such
factors are ﬁxed characteristics (e.g., sex, race), some are
biologic features (e.g., cholesterol level), some are be-
haviors (e.g., smoking), some can be modiﬁed by in-
terventions, and some cannot. Fortunately, the method
for incorporating risk factors in the trajectory of a
feature works for all types of risk factors. In the fol-
lowing discussion, we will refer to incorporating a de-
pendence on features, with the understanding that the
method can easily incorporate dependence on other risk
factors.
Begin by observing that the dependence of one fea-
ture on other features is already incorporated in the data
and therefore is incorporated in the coeﬃcients and
basis functions estimated for each individual in Eqs. (3),
(11), or (23). Our task is to separate out that dependence
and to represent it explicitly in the coeﬃcients or basis
functions of the equations for the trajectory of the fea-
ture. We need to do this if we are to develop a general
model that can be used to analyze interventions, not
only in clones of the original population, but also in a
wide variety of other populations that will have diﬀerent
distributions of risk factors.
The separation of the dependence on other features
requires care, because the data for estimating the
equations for a feature contain all the dependence of
the feature on age. But the data are not separated into
the dependence of the feature as a function of age, at a
ﬁxed value of another feature, or the dependence of the
feature as a function of another feature, at a ﬁxed age.
The dependence we want to address can be repre-
sented either in the coeﬃcients or in the basis functions.
In the hybrid expansion, the dependence is represented
in the basis functions or in both the basis functions and
the coeﬃcients. In the hybrid expansion, it is easy to
include the dependence of one feature on another be-
cause the independent features (such as cholesterol level
in the trajectory for coronary artery occlusion) can be
explicitly separated out and included in the expansion as
its own basis function. The trade-oﬀ is that the hybrid
expansion is not guaranteed to converge and the equa-
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tions for determining the coeﬃcients for the hybrid
expansion may be ill conditioned. In the Fourier ex-
pansion, the dependence is represented in the coeﬃ-
cients. Here, we will describe how to determine the
distributions of the coeﬃcients from the available data,
when the features are related in a Fourier expansion and
one feature depends on another.
Drawing on the notation of Eqs. (24) and (25), we
can consider the distributions of the coeﬃcients of the
random process for the ith feature, Fiðx; tÞ, to depend
on the coeﬃcients of the random processes of other
features. Let s^iðxÞ represent the coeﬃcients of the ex-
pansion terms for the random processes of all features
other than feature i (i.e., all si0jðxÞ for i0 6¼ i and all j),
and let x^i represent speciﬁc values that the coeﬃcients
can take for all features other than feature i. To allow
the distributions of the coeﬃcients of the ith feature to
be conditional on the coeﬃcients of other features, we
represent the parameters of the distributions for the ith
feature to be functions of the coeﬃcients of the distri-
butions of other features, that is, ~Hijðx^Þ. Using this
notation,
P ðx < sijðxÞ < xþ dxjs^iðxÞ ¼ x^iÞ ¼ qijðxj~Hijðx^iÞÞ: ð26Þ
The ~Hijðx^Þ can be made functions of the coeﬃcients x^i in
many diﬀerent ways. One choice is to use an expansion
that is linear in the coeﬃcients,
~Hijðx^iÞ ¼ ~Hij ~bij0
0
@ þ XI
i0 6¼i; all j0
~biji0j0xi0j0
1
A: ð27Þ
In general, let ~B be the coeﬃcients that deﬁne the
functional representation of ~Hijðx^Þ. (If the functional
representation is a linear expansion, then ~B ¼ f~bij0~biji0j0 g.
The likelihood of obtaining all the sample values skij for
all the individuals k ¼ 1 . . .K, and all the features i, and
the coeﬃcients of all the terms of the expansion (indexed
by j) is given by the equation
Lð~Bj~sÞ ¼
YK; I
k¼1;i; all j
qij s
k
ijj~Hijðx^iÞ

 
; ð28Þ
where~s represents the set of all coeﬃcients obtained by
observations on all people. The ~B are determined by
maximizing the likelihood in Eq. (28).
In practice, most features are either independent or
depend on only a few other features. In the latter sit-
uation, variables that depend on each other can be
grouped together, isolated as a group, and estimated
separately from the rest. The particular model chosen
for the dependencies, whether it involves the Fourier
expansion or the hybrid expansion, will be diﬀerent for
diﬀerent features and health conditions, depending on
the biology and the available data. How well the model
addresses any dependencies between biological vari-
ables will ultimately be tested in the validation exer-
cises.
12. Equations that relate events to features
After functions have been derived for the natural
trajectories of features, linking features to events is fairly
straightforward. First, because any biological variable
can be represented in the model as a feature, biologic
events are represented by the values of features; tests can
be applied to measure the value of a biological feature at
any time. Uncertainty, random errors, and systematic
errors in tests are easy to include.
For clinical events, more work is required. If the
clinical event is directly related to the feature (as, for
example, occlusion of a coronary artery can be observed
through an infarction), the trajectory will automatically
reproduce the occurrence of the clinical event as re-
quired. Otherwise, it is necessary to describe or model
how the clinical event is linked to the feature. The ap-
propriate model will depend on the data available. For
example, a standard medical text [10] suggests that an-
gina pain tends to occur when degree of coronary artery
occlusion approaches 70%. Clinical events can also be
deﬁned as more complex functions of one or more fea-
tures. For example, rapid weight change in a patient
with congestive heart failure is an indication to regulate
the dose of diuretics. Because values of all features are
always available in continuous form through the equa-
tions for their trajectories, it is relatively easy to deﬁne
models that determine the occurrence of clinical events
as functions of the values of several features. For ex-
ample, clinical diabetes can be deﬁned as either a fasting
plasma glucose level >126mg/dL or a glucose tolerance
test result >200mg/dL.
13. Eﬀects of interventions
Eﬀects of health interventions can be modeled either
as a change in the value of a feature, the rate of change
of a feature, or a combination of the two. The choice
and the exact model will depend on the biology of the
disease, the mechanism of action of the intervention,
and the available data.
14. Application of the methods
The methods described in the previous sections can be
used to estimate the trajectories of features, for a variety
of diﬀerent types of available evidence. In practice, a
model for a speciﬁc disease is developed as follows.
1. We begin with a description of the physiology and
pathophysiology pertinent to the disease. This de-
scription is obtained from textbooks, review papers,
and experts.
2. We next develop a nonquantitative, conceptual mod-
el of the disease that identiﬁes all the important
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biological variables and their relationships. This can
be represented by a ﬁgure with circles representing
the variables and lines or arrows representing the re-
lationships between variables. At this time, we also
identify the primary feature or features that ‘‘cause’’
the disease and that are responsible for its progres-
sion. One or more of the primary features may be vir-
tual, depending on how well the causes of the disease
are understood.
3. We next identify the physiological, clinical, and epi-
demiological research studies that form the basis for
the current knowledge of the disease.
a. Ideally, there will be a database that contains lon-
gitudinal, person-speciﬁc data on all the important
biological variables and clinical outcomes. When
such data exist, either the Fourier expansion or
the hybrid method can be used to derive equations
for the features. The resulting equations will incor-
porate any dependencies between features that can
be identiﬁed in the data.
b. When person-speciﬁc data are not available for a
disease, we use the studies that form the current
knowledge base for the disease. Typically, there
are dozens of studies of various designs that ad-
dress particular variables or sets of variables and
their relationships. For example, a large epidemio-
logical study might provide information on the
age- and sex-speciﬁc incidence rates for various ra-
cial and ethnic groups; a regression equation from
another large database might give the eﬀects of bi-
ological risk factors; a clinical trial might provide
information about the eﬀects of changing one of
those biological variables; and so forth. Just as ex-
perts do cognitively, we will use these pieces to
build a model of the disease by integrating the in-
formation from all the sources that experts con-
sider to be important. The main diﬀerences are
that our model will be quantitative and can be
subjected to validation.
c. Even when person-speciﬁc data are available, there
are invariably important aspects of the disease that
are not completely addressed by the database. We
use additional studies to complete the picture of
the disease as just described.
4. The model is then ready for validation.
Throughout this process, we are guided by experts.
They provide an initial description of the disease, de-
termine the appropriate level of biological and clinical
detail, help identify the research studies that form the
knowledge base for the disease, help identify clinical
trials and other studies that can be used for validations,
help interpret the validations, and help identify new
technologies and research results that should be incor-
porated in new versions of the model. However, we do
not use any expert subjective judgments for variables
in the model. All of the equations and parameters are
derived from at least one actual research study (except
for ‘‘what-if’’ calculations).
15. Validation
Ultimately, the validity of everything—the basic for-
mulation, the choice of objects to represent the anatomy
and physiology, the use of virtual features, the methods
for deriving equations, the modeling of dependencies
between features, and the combination of results of
diﬀerent studies—is determined by how well the model
can reproduce and predict empirical observations. We
evaluate the validity of the model through four diﬀerent
types of exercises. The ﬁrst is that each of the equations
must ﬁt the data used to derive them. These exercises
help ensure that each individual piece of the model is an
accurate representation of the results of a particular
study, but they do not test the connections between
pieces or the consistency of results across studies. We
call these ‘‘one-star’’ validation exercises.
The other three types of validation exercises are far
more challenging, and draw on the ability of an Archi-
medes model to simulate clinical scenarios at a high level
of detail. They involve simulating clinical studies and
comparing the simulated results with the real results.
The basic steps for this type of validation are: (1) Have
the model ‘‘give birth’’ to a large population of simu-
lated people. (2) Run the model to let them age naturally
until they reach the ages of the people who were can-
didates for the trial. (3) Identify those who would meet
the entry criteria for the trial and select from them a
sample that corresponds to the sample size of the real
trial. (4) Randomize the simulated participants into
groups and have simulated providers give them the
treatments described in the trial. (5) Run the model for
the duration of the trial. (6) Count the biological and
health outcomes of interest that occurred to the partic-
ipants in the simulated trial and compare them to the
results observed in the real trial. A full validation re-
quires several such exercises. For each exercise, we look
at three things: ‘‘matching,’’ ‘‘span,’’ and ‘‘indepen-
dence.’’ We also look at the ‘‘comprehensiveness’’ of the
full set of validation exercises.
For matching, we ask how closely the results of the
simulated study match those of the real study. Because it
is a true simulation, the simulated results will be aﬀected
by sample size in an identical way as the results of the
real trial. We say there is ‘‘statistical matching’’ when
the simulated results match the real results within ap-
propriate conﬁdence intervals. Because smaller trials
have wider conﬁdence intervals, they are easier to
match. We therefore seek out trials that have suﬃcient
size to provide a meaningful test and ask that the match
be within one standard deviation, not the traditional
95% conﬁdence interval. We can also increase the
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number of people in the simulation to tighten the con-
ﬁdence intervals for the simulation’s results.
‘‘Span’’ refers to the number of equations the vali-
dation covers. We consider validations that span mul-
tiple equations to be disproportionately more important
than one-equation validations because they test not only
individual pieces of the model but all the possible con-
nections between them. Simulation of a typical clinical
trial can involve scores of equations.
For ‘‘independence’’, we identify three main levels of
validation. We call the exercise a ‘‘two-star’’ validation
when the results being compared were used to ﬁt one or
more of the equations. For a ‘‘three-star’’ validation, the
exercise should compare outcomes in a study that were
not used to ﬁt the equations. For example, we might use
the eﬀect of a treatment on LDL-cholesterol after one
month to set up a validation and then use the rate of
strokes at 10 years to validate it. Such an exercise can be
considered a ‘‘partial prediction’’ in the sense that the
outcomes being calculated were never used by the
model; long-term outcomes might be predicted from
short-term outcomes or health outcomes might be pre-
dicted from biological outcomes. Finally, the model can
simulate trials whose results were not used at all to build
the model. This would represent a ‘‘full prediction’’ and
we call it a ‘‘four-star’’ validation.
Finally, ‘‘comprehensiveness’’ refers to the portion of
the total model covered by the full set of validation
exercises to which the model was subjected. For a fully
comprehensive validation of an application, every
equation involved in calculating an outcome of interest
should be covered by at least one validation exercise.
This approach to validation implies that a model can be
validated for certain applications (e.g., calculating the
eﬀect of a particular treatment on a particular outcome),
but not validated for a diﬀerent application (e.g., the
eﬀect of a diﬀerent treatment that is less well under-
stood). We do not consider the model to be ‘‘valid’’ in
any general sense, as though it were a property of the
model for all possible applications.
16. Discussion
This model diﬀers from other models in health care in
several ways. First, it is an object-oriented simulation.
All of the objects considered by clinicians and admin-
istrators to be important are represented as objects in
the model, one-to-one. Second, it is written at a high
level of anatomic, biologic, and clinical detail—roughly
the level of detail at which clinical textbooks are written
and research is designed. Unlike other models that in-
clude biological variables as inputs, an Archimedes
model is continuously calculating all the pertinent bio-
logical variables and their interactions as part of a
simulated physiology. This enables the model to analyze
detailed practice guidelines, disease management pro-
grams, and performance measures. It also enables the
model to address combinations of interventions and
comorbidities in a natural way. Finally, the biological
grounding of the model makes it easy to revise when
new information becomes available or new interven-
tions are introduced. A third diﬀerence is its breadth.
The model includes not only diseases and the clinical
interventions that aﬀect them, but also the other ele-
ments of a health care system such as care processes,
facilities, personnel, equipment, and budgets. These as-
pects of the model are also written at a high level of
detail, as determined by the needs of clinicians and
administrators.
Mathematically, the model is distinguished by the use
of diﬀerential equations. This has two important eﬀects.
One is to preserve the continuous nature of biological
variables. For example, fasting plasma glucose (FPG) is
not modeled in discrete states such as ‘‘normal,’’
‘‘prediabetes,’’ and ‘‘diabetes.’’ Rather, the FPG of ev-
ery person is calculated continuously as part of a per-
son’s physiology and can be measured at any instant. All
the biological variables and interactions pertinent to the
clinical management of a problem are calculated in this
way. The use of diﬀerential equations also makes the
model completely continuous in time; any event can
occur at any moment. This is important because many
decisions in health care involve timing. Examples in-
clude how frequently to screen a person or monitor a
patient; when to initiate, modify or switch a treatment
strategy; how frequently to schedule follow-up visits; the
dependence of the sensitivity of a test on the degree of
development of a disease (e.g., size of a mass); and the
eﬀectiveness of a treatment on the time it is given (e.g.,
thrombolytics for myocardial infarctions).
A ﬁnal distinction is the method of validation. The
fact that Archimedes is a detailed object-oriented sim-
ulation model provides a rigorous way to conduct vali-
dations; the model can be asked to reproduce or predict
the results of real clinical trials. These simulations test
dozens of equations and their interactions. Simulations
of several trials can criss-cross diﬀerent parts of the
model in ways that make successful matches exceedingly
unlikely to be due to chance, and that virtually ensure
that the underlying formulation of the physiology is
accurate.
The level of detail of the model is determined by three
things. The ﬁrst is the level of detail of the clinical and
administrative questions being asked. For example, if
the intention is to analyze a disease management pro-
gram for congestive heart failure, and one of the vari-
ables clinicians are debating is the degree of cardiac
failure that should be used to assign patients to a case
manager (e.g., ejection fractions less than 50% versus
ejection fractions less than 40%), then the model has to
include cardiac output and ejection fraction, and all the
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other variables that determine them and might be af-
fected by treatments (e.g., myocardial contractility). The
second determinant is the level of detail clinicians re-
quire to have conﬁdence that the model includes all the
relevant factors. In general, this means that the model
will include all the variables they use to determine the
management of a patient. The third determinant of the
model’s detail is the availability of research studies that
provide empirical information about the variables.
The last criterion means that the scope, depth, and
uses of the model will ultimately depend on the quantity
and quality of the available studies. Because the model is
written at the level of physiological detail that matches
the available research, there is a straightforward ap-
proach to ﬁnding information about a variable: When
experts consider a variable to be important, it is almost
always because there is research that demonstrates its
importance; that research can be used to include the
variable in the model. A corollary of this is that if there
is a well-designed study that addresses a particular set of
variables, then the results of that study can be used to
include those variables. Conversely, if there are no good
studies that address a particular variable or set of vari-
ables, then the model will not include those variables for
use in a predictive fashion.
As with any model, if there are important omissions
or errors in a dataset, if there are biases or omissions in
the conduct or reporting of a study, the equations will be
thrown oﬀ accordingly. Furthermore, because the
equations for diﬀerent parts of the model can come from
diﬀerent sources and because of the possibility that the
diﬀerent sources might be from diﬀerent populations
and/or use diﬀerent methods, there is always a risk of
producing a camel—a model that might be correct in its
parts, but is not accurate in the whole. The best way to
test this is through the validation exercises.
The types of simulations that can be performed by the
model provide very deep validations. Even a two-star
validation is much more diﬃcult and meaningful than
for other types of models because of the large number of
equations that are required to make the physiologies of
the agents function accurately enough to just survive the
simulation, much less to match the real results accu-
rately. For example, simulation of an epidemiological
study of the incidence of a disease requires that about a
dozen pieces of the model all function properly, not just
as separate parts, but in a connected way. They include
the equations that govern the progression of the primary
features that cause the disease as functions of all the
pertinent risk factors; the occurrence of symptoms as a
function of the primary features; the behavior of pa-
tients in recognizing and seeking care for symptoms; the
making of appointments for the symptoms; the ordering
of tests by simulated physicians; the accuracies of the
tests; the interpretation of the tests to make the diag-
nosis; and the accurate calculation of incidence rates by
a simulated epidemiologist. Simulations of clinical trials
that involve several diﬀerent treatment protocols (e.g.,
‘‘treat LDL-cholesterol to a goal of 130mg/dL’’) add
higher orders of diﬃculty.
Three- and four-star validations provide even greater
conﬁdence that the model’s representation of human
physiology and disease is accurate. However, the ‘‘fail-
ure’’ of a three- or even four-star validation does not
necessarily mean that the model was wrong. One reason
is that diﬀerent trials that appear to be addressing the
same question can produce diﬀerent results. The model
will be just as confused by this as are experts. A second
reason is that trials often produce surprising results. A
four-star validation means that the results of the trial
were completely predictable from existing information
(predictable by the model at least). If a trial’s results are
surprising to experts, they will be surprising to the
model. It should also go without saying that the model
cannot predict events that have never been observed.
For example, the model would not have predicted that
fen-phen (fenﬂuramine, phentermine, and dexfenﬂur-
amine) would aﬀect mitral valves.
With these limitations in mind, when new or sur-
prising results occur, they can be incorporated into the
model at the level of biologic detail at which the
mechanisms of action are understood to occur. As
more and more observations are incorporated into the
model, the equations describing the underlying biology
of diseases and their treatments become increasingly
robust.
For parts of the model that are spanned by overlap-
ping validations, the model can be used for a variety of
purposes. They include: (1) combining the results of
existing research (e.g., comparing two treatments that
have been well researched separately, but never com-
pared directly); (2) analyzing combinations of treat-
ments (e.g., treat LDL cholesterol, blood pressure, and
weight); (3) analyzing issues of timing; (4) extending the
results of trials into the future (e.g., calculating long-
term health outcomes from short-term biological out-
comes); (5) extending research to diﬀerent populations
(e.g., patients with more severe diseases, or with diﬀerent
combinations of risk factors; (6) analyzing the eﬀects of
changes in care processes (e.g disease management
programs, continuous quality improvement programs);
(7) analyzing the eﬀects of clinical interventions and care
processes on logistics and costs; (8) trying out diﬀerent
guidelines and disease management programs to im-
prove their designs and suggest short-term outcomes
that should be monitored to conﬁrm their eﬀects; (9)
identifying the most important determinants of an out-
come; (10) developing quantitative rankings of diﬀerent
interventions across diseases, for setting priorities and
designing performance measures; (11) determining the
extent to which the results of a program observed in one
setting are transferable to other settings and the factors
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that determine the transferability; (12) conducting cost-
eﬀectiveness analyses; and (13) planning research.
Although it is not the subject of this paper, a note
about the modeling of care processes is appropriate. In
practice, we develop our models of care processes
through examination of existing protocols, interviews,
and on-site observations, checked against any available
data. Pilot studies can be conducted as needed. Many of
the data required to model system resources have al-
ready been collected for administrative purposes.
However, some are more problematic. An example is
how much money will be saved if a resource is not used
(e.g., a bed goes empty because a myocardial infarction
is prevented, but no nurses are laid oﬀ). In such cases,
administrators must describe how they would handle
diﬀerent scenarios and must understand that the accu-
racy of the results will depend on the accuracy of their
descriptions. Any decision rules they might apply can be
easily added to the model (by putting simulated ad-
ministrators in the model and giving them a function of
applying the decision rules).
As with any model, the key to addressing the data
problem, whether it is on the clinical or logistic side of
the model, is to appreciate that as the quality of the
evidence varies the appropriate uses of the model
change. At one extreme, if the parts of the model per-
tinent to a particular application can be well validated,
then it is reasonable to act on the model’s results. At the
other extreme, if there is no information at all about
certain variables, uses of the model that require those
variables should be restricted to building understanding.
The appropriate techniques here include ‘‘what if’’ cal-
culations, identiﬁcation of the most critical variables,
identiﬁcation of upper and lower bounds for an out-
come, and planning of research. As with any model,
sensitivity analysis can be used to explore the vulnera-
bility of a conclusion to any particular variable or
combination of variables.
Currently, the model includes the biological variables
pertinent to coronary artery disease, congestive heart
failure, diabetes, and asthma. About 6 months is needed
to add a new disease. The model is programmed in
Smalltalk (a pure object environment and programming
language) and runs on any personal computer. A typical
calculation for a medical center serving 300,000 people
takes 24–72 hours. Computation times can be reduced
by running parallel calculations.
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